Chinese bulk aspirin
This article was originally published in The Tan Sheet
Executive Summary
Jilin Henghe Pharmaceutical and Shandong Xinhua Pharmaceutical did not sell bulk aspirin in the U.S. "below normal value" from July 1, 2001 through June 30, 2002, International Trade Administration says Aug. 13. ITA determines no antidumping duties should be imposed on the two Chinese companies; antidumping margin of 144% applicable to other bulk aspirin exporters based in the People's Republic of China remains unchanged. In July 2000, U.S. Customs service imposed antidumping duties of 16.5% on Shandong, 10.9% on Jilin (1"The Tan Sheet" July 3, 2000, p. 2)...
You may also be interested in...
Aspirin dumping
U.S. Customs service will impose antidumping duties on bulk aspirin imports from China following a June 22 ITC determination the imports threaten U.S. industry with material injury. In an amended final determination June 21, the ITA revises previously announced weighted-average dumping margins for two Chinese firms: Shandong Xinhua Pharmaceutical Factory, 16.5% (previously 42.8%) and Jilin Pharmaceutical, 10.9% (previously 4.7%). The PRC-wide rate of 144% is unchanged (1"The Tan Sheet" May 29, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.